Journal Mobile Options
Table of Contents
Vol. 35, No. 2, 2013
Issue release date: March 2013
Cerebrovasc Dis 2013;35:131–137

Early Inhibition of Natriuresis Suppresses Symptomatic Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage

Nakagawa I. · Hironaka Y. · Nishimura F. · Takeshima Y. · Matsuda R. · Yamada S. · Motoyama Y. · Park Y.-S. · Nakase H.
Department of Neurosurgery, Nara Medical University, Kashihara, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Hyponatremia is a common complication occurring in one third of patients after subarachnoid hemorrhage (SAH). One mechanism that likely mediates the development of hyponatremia in SAH is cerebral salt wasting syndrome (CSWS), which induces natriuresis and reduces total blood volume, resulting in a risk of symptomatic vasospasm (SVS). The mineral corticoid fludrocortisone acetate enhances sodium reabsorption in the renal distal tubules and may help prevent post-SAH hyponatremia. However, management with fludrocortisone acetate is ineffective if hyponatremia is advanced, because CSWS and subsequent SVS develop rapidly. Therefore, an additional earlier marker is required to predict the development of hyponatremia for the initiation of immediate treatment in select patients. However, no conclusive evidence exists showing that hyponatremia influences the risk of SVS, and no standard treatment protocol exists for treating hyponatremia in patients with SAH. This study was undertaken to evaluate whether selective early treatment of hyponatremia prevents SVS in patients with increased urinary sodium excretion in the early phase following SAH. Methods: A total of 103 patients with aneurysmal SAH were managed for a postoperative electrolyte disorder after aneurysmal clipping or coil embolization. Between 2004 and 2007 (period 1), 54 patients started treatment to correct the electrolyte disorder after hyponatremia had occurred. Between 2007 and 2011 (period 2), 49 patients were prospectively subjected to sodium replacement treatment according to their daily sodium balance, and inhibition of natriuresis with fludrocortisone acetate was initiated just after an increase in urinary sodium excretion >300 mEq/day. The occurrence of hyponatremia, SVS, and outcomes were compared between the two periods. Results: Hyponatremia was observed in 14 patients (26%) in period 1 and 7 patients (14%) in period 2. The incidence of fludrocortisone acetate administration was significantly higher, and initiation of electrolyte correction was significantly earlier, in period 2 patients. We observed a significant difference in the frequency of SVS, which occurred in 10 patients (18.5%) in period 1 and 3 patients (6.1%) in period 2. Both urinary sodium excretion and urine volume at day 7 were significantly different between the two periods. However, no significant difference was observed in overall outcome between the two periods. Conclusions: Early inhibition of natriuresis with fludrocortisone acetate before the occurrence of hyponatremia prevented SVS after aneurysmal SAH. Increased urinary sodium excretion in the early phase of SAH is a good indicator for the initiation of electrolyte correction with fludrocortisone acetate.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Harrigan MR: Cerebral salt wasting syndrome: a review. Neurosurgery 1996;38:152–160.
  2. Peters JP, Welt LG, Sims EA, Orloff J, Needham J: A salt-wasting syndrome associated with cerebral disease. Trans Assoc Am Physicians 1950;63:57–64.

    External Resources

  3. Isotani E, Suzuki R, Tomita K, Hokari M, Monma S, Marumo F, Hirakawa K: Alterations in plasma concentrations of natriuretic peptides and antidiuretic hormone after subarachnoid hemorrhage. Stroke 1994;25:2198–2203.
  4. McGirt MJ, Blessing R, Nimjee SM, Friedman AH, Alexander MJ, Laskowitz DT, Lynch JR: Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. Neurosurgery 2004;54:1369–1373, discussion pp 1373–1374.
  5. Nakagawa I, Kurokawa S, Nakase H: Hyponatremia is predictable in patients with aneurysmal subarachnoid hemorrhage – clinical significance of serum atrial natriuretic peptide. Acta Neurochir (Wien) 2010;152:2147–2152.
  6. Sviri GE, Shik V, Raz B, Soustiel JF: Role of brain natriuretic peptide in cerebral vasospasm. Acta Neurochir (Wien) 2003;145:851–860, discussion p 860.
  7. Nelson RJ, Perry S, Burns AC, Roberts J, Pickard JD: The effects of hyponatraemia and subarachnoid haemorrhage on the cerebral vasomotor responses of the rabbit. J Cereb Blood Flow Metab 1991;11:661–666.
  8. Wijdicks EF, Vermeulen M, Hijdra A, van Gijn J: Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful? Ann Neurol 1985;17:137–140.
  9. Igarashi T, Moro N, Katayama Y, Mori T, Kojima J, Kawamata T: Prediction of symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage: relationship to cerebral salt wasting syndrome. Neurol Res 2007;29:835–841.
  10. Morinaga K, Hayashi S, Matsumoto Y, Omiya N, Mikami J, Sato H, Inoue Y, Okawara S, Ishimaru K: Therapeutic effect of a mineralocorticoid in patients with hyponatremia of central origin (in Japanese). No To Shinkei 1995;47:671–674.

    External Resources

  11. Hasan D, Wijdicks EF, Vermeulen M: Hyponatremia is associated with cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. Ann Neurol 1990;27:106–108.
  12. Mori T, Katayama Y, Kawamata T, Hirayama T: Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1999;91:947–952.

    External Resources

  13. Morinaga K, Hayashi S, Matsumoto Y, Omiya N, Mikami J, Ueda M, Sato H, Inoue Y, Okawara S: Serum ANP and ADH after subarachnoid hemorrhage and hyponatremia (in Japanese). No To Shinkei 1991;43:169–173.

    External Resources

  14. Nakagawa I, Kurokawa S, Takayama K, Wada T, Nakase H: Increased urinary sodium excretion in the early phase of aneurysmal subarachnoid hemorrhage as a predictor of cerebral salt wasting syndrome (in Japanese). Brain Nerve 2009;61:1419–1423.

    External Resources

  15. Hunt WE, Kosnik EJ: Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg 1974;21:79–89.

    External Resources

  16. Fisher CM, Kistler JP, Davis JM: Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1–9.

    External Resources

  17. Qureshi AI, Suri MF, Sung GY, Straw RN, Yahia AM, Saad M, Guterman LR, Hopkins LN: Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2002;50:749–755, discussion pp 755–756.
  18. Wijdicks EF, Ropper AH, Hunnicutt EJ, Richardson GS, Nathanson JA: Atrial natriuretic factor and salt wasting after aneurysmal subarachnoid hemorrhage. Stroke 1991;22:1519–1524.
  19. Atchison JW, Wachendorf J, Haddock D, Mysiw WJ, Gribble M, Corrigan JD: Hyponatremia-associated cognitive impairment in traumatic brain injury. Brain Inj 1993;7:347–352.
  20. Okuchi K, Fujioka M, Fujikawa A, Nishimura A, Konobu T, Miyamoto S, Sakaki T: Rapid natriuresis and preventive hypervolaemia for symptomatic vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien) 1996;138:951–956, discussion pp 956–957.
  21. Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, Schulte M, von Wild K, Scherer R: Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997;349:245–249.
  22. Kubo Y, Ogasawara K, Kakino S, Kashimura H, Yoshida K, Ogawa A: Cerebrospinal fluid adrenomedullin concentration correlates with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. Cerebrovasc Dis 2008;25:164–169.
  23. Moro N, Katayama Y, Kojima J, Mori T, Kawamata T: Prophylactic management of excessive natriuresis with hydrocortisone for efficient hypervolemic therapy after subarachnoid hemorrhage. Stroke 2003;34:2807–2811.
  24. Benvenga S: What is the pathogenesis of hyponatremia after subarachnoid hemorrhage? Nat Clin Pract Endocrinol Metab 2006;2:608–609.
  25. Katayama Y, Haraoka J, Hirabayashi H, Kawamata T, Kawamoto K, Kitahara T, Kojima J, Kuroiwa T, Mori T, Moro N, Nagata I, Ogawa A, Ohno K, Seiki Y, Shiokawa Y, Teramoto A, Tominaga T, Yoshimine T: A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. Stroke 2007;38:2373–2375.
  26. Rahman M, Friedman WA: Hyponatremia in neurosurgical patients: clinical guidelines development. Neurosurgery 2009;65:925–935, discussion pp 935–936.
  27. Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N, Connolly ES, Mayer SA: Clinical response to hypertensive hypervolemic therapy and outcome after subarachnoid hemorrhage. Neurosurgery 2010;66:35–41, discussion p 41.
  28. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, Wu YC, Klebanoff LM, Raps EC, Solomon RA: Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke 2000;31:383–391.
  29. Mayer SA, Solomon RA, Fink ME, Lennihan L, Stern L, Beckford A, Thomas CE, Klebanoff LM: Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage. Neurosurgery 1998;42:759–767, discussion pp 767–768.
  30. Suarez JI, Shannon L, Zaidat OO, Suri MF, Singh G, Lynch G, Selman WR: Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage. J Neurosurg 2004;100:585–590.
  31. Wong GK, Poon WS: Risk of high dose hydrocortisone in patients with aneurysmal subarachnoid hemorrhage. Stroke 2008;39:e12, author reply p e13.
  32. Wijdicks EF, Vermeulen M, van Brummelen P, van Gijn J: The effect of fludrocortisone acetate on plasma volume and natriuresis in patients with aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1988;90:209–214.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50